ASH 2022 | Initial results with the use of MS-553 in patients with CLL/SLL
James Blachly, MD, The Ohio State University, Columbus, OH, briefly discusses results from a study which is investigating the efficacy of MS-553, a protein kinase C (PKC) β inhibitor, in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (NCT03492125). Overall, early results indicate an encouraging response rate with MS-553 among this heavily pre-treated patient population. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
KITE Pharma: Consultancy, Membership on an entity’s Board of Directors or advisory committees; AstraZeneca: Consultancy, Membership on an entity’s Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity’s Board of Directors or advisory committees; MingSight Pharmaceuticals: Other: Clinical trial funding, Research Funding.
